Aims To conduct a randomized, parallel group comparison of the population pharmacokinetics of the two methylprednisolone (MP) prodrugs Promedrol (MP suleptanate) and Solu-Medrol (MP succinate) Conclusions It was concluded that for the multiple dosage regimen used in patients with acute asthma the systemic exposure to MP following dosing with MP suleptanate is similar to that arising from MP succinate. In addition the differences in the pharmacokinetics for the prodrugs resulted in only a small difference in the relative bioavailability of MP for MP suleptanate (0.94) compared with MP succinate.
bioequivalence studies using a cross-over design have shown Introduction that the AUCs for MP are very similar, whereas there are differences in the MP C max between the two prodrugs (MP 6-a-Methylprednisolone, MP; MedrolA) has been marketed as an injectable corticosteroid in the form of the sodium suleptanate higher than MP succinate). However, these differences in C max are unlikely to be of clinical significance. succinate ester (MP succinate; Solu-Medrol) for more than 20 years. MP succinate is not stable in solution and is
The main purpose of the present study was to examine whether MP suleptanate and MP succinate produce similar therefore marketed as a freeze-dried product that requires reconstitution resulting in inconvenience, waste, loss of safety and efficacy profiles in patients treated with the prodrugs for acute asthma. As part of this study, limited time in preparation, and added cost. Methylprednisolone 21-{8-(2-sulphoethyl ) methyl amino}-8-oxo-octanoate, blood sampling of the patients was undertaken in order to investigate the pharmacokinetics of MP in a patient sodium salt (MP suleptanate; Promedrol) is being developed as a pharmaceutical alternative to MP succinate and will be population receiving either MP suleptanate or MP succinate. Essentially this was a population comparative bioavailability available as a ready to inject solution.
Both MP suleptanate and MP succinate are prodrug esters study which determined whether a multiple dosage regimen of either prodrug results in similar exposures to MP. that are converted to the active agent, MP by the action of esterase enzymes in vivo. Studies in animals and man show that the pharmacokinetics of MP released from MP suleptanate are similar to those of MP succinate and that the Methods elimination of MP is the same whether derived from MP succinate or MP suleptanate [1] [2] [3] [4] patients hospitalised with acute asthma. Both prodrugs were supplied by the clinical trials supply department of Pharmacia regression (1/x 2 ) and linearity (r 2 ) was 0.99 or better. Two calibration ranges were used in order to measure the wide & Upjohn Inc. (Crawley, UK). The investigational treatment was given for 48 h as a bolus intravenous injection of 40 mg range of sample concentrations. The lower limit of quantification for the procedure was 10 ng ml −1 and quality control (MP equivalents) at 6 hourly intervals. At 48 h corticosteroid therapy was continued with oral administration of one samples prepared at twice this concentration were measured with a coefficient of variation for the study of less than 20%. 32 mg dose of Medrol. Plasma samples were collected from 90 patients (45 patients for each prodrug). A maximum of At higher concentrations the coefficient of variation was found to be 7.3% or lower. three plasma samples were collected per patient within the 48h study period. These were drawn after any dose but within three specified time intervals: (i) within 30 min of a Pharmacokinetic analysis dose, (ii) between 30 min and 3 h of a dose, (iii) between Due to the limited plasma concentration data available, 3 and 6 h of a dose.
pharmacokinetic analysis was carried out using NONMEM (Version IV), which enables estimation of population Patients pharmacokinetic parameters using the method of extended least squares [5] . Patients included in this study had symptoms consistent with the American Thoracic Society criteria for the diagnosis of Pharmacokinetic model Plasma MP levels for either prodrug asthma. The study was reviewed and approved by the Ethics were best described using a one compartment model with Committee at each of the five investigational centres. All first order input and mono-exponential elimination. Initial volunteers received full study details before signing an estimates of the pharmacokinetic parameters were based on informed consent form. There were no significant differences data from an earlier study for a single 40 mg i.v. dose of between the groups receiving either MP suleptanate or MP MP suleptanate or MP succinate, with model fitting succinate with regard to demographics, cigarette smoking performed in SIPHAR Version 4.0 [6] . The first order input or clinical status. There were slight differences between of the model described the bio-conversion of MP suleptanate groups with respect to the mean age of onset of asthma or MP succinate to MP after an i.v. dose. Steady-state MP (12.8 years, MP suleptanate; 16.9 years, MP succinate ( P= levels for both prodrugs administered in a 6 hourly dosing 0.093)). However, no significant differences were observed regimen, were reached at 18 h post-dose. The population for frequency of attacks per month, duration of current pharmacokinetic parameters estimated for these data and attack, previous hospitalisation for asthma, reporting of dosing regimen were clearance (CL), volume of distribution chronic symptoms (cough, wheeze, sputum and chest pain) (V ), input rate constant (ka). The bioavailability ( F) was or previous requirement for ventilatory support because of set to unity for MP succinate, and estimated as a further asthma. Volunteers were permitted to use a 'standard' parameter, relative to MP succinate, for MP suleptanate. regimen of concomitant therapies to treat the asthmatic attack. These included inhaled bronchodilators, oral
Pharmacostatistical model Random effects consist of interindibronchodilators or intravenous theophylline/aminophylline. vidual variability (g) on each parameter and residual variability (e) which encompasses measurement error, model Drug analysis missspecification and intraindividual error. A comparison of error models for each parameter showed no benefit in using Blood samples (5 ml) were collected in EDTA tubes, a more complicated model than a simple additive one in centrifuged and stored at −20°C prior to analysis. Plasma describing the interindividual and residual variation: samples were analysed for MP concentration at Pharmacia & Upjohn Inc., Crawley, using an in-house developed CL j =Ĉ L j +g jCl method combining solid phase extraction with reversed V j =V j +g jV phase h.p.l.c. ka j =ka j +g jka An aliquot of plasma (0.25 ml or less) was fortified with internal standard solution (dexamethasone), diluted with Cp ij =Ĉ p ij +e ij water and drawn through a primed Bond Elut C2 extraction cartridge. The cartridge was washed with water and
Covariate analysis The influence of various covariates on the population mean parameter values were investigated. methanol5water (20580 v/v) before elution with acidified acetonitrile5water (50550 v/v). The eluates were partially
The covariates included indicator variables and the continuous variable body weight. Indicator variables included evaporated in situ and some or all of the extract analysed by reversed phase h.p.l.c. with u.v. detection at 251 nm. administered prodrug (zero=MP succinate, unity=MP suleptanate), gender (zero=male, unity=female), smoking The h.p.l.c. stationary phase used was Spherisorb ODS II (250×4.6 mm) maintained at 45°C using a forced air status (zero=non-smoker, unity=one or more cigarettes smoked a day), race (zero=white Caucasian, unity=other column oven. The mobile phase consisted of acetonitrile5tri-fluroacetic acid5water (3350.15566.85 v/v/v) at 2 ml race). The indicator variables were added individually to the parameters of the basic model. The body weight (kg) of min −1 . Retention times obtained using the described system were: MP, 6.8 minutes and dexamethasone, 7.6 min. The each individual was incorporated into the volume parameter of the model. NONMEM computes a statistic for each total run time was approximately 10 min. The chromatography was efficient (36,000 theoretical plates m −1 ), and robust. analysis, the minimum objective function value, which corresponds to minus twice the log likelihood of the data. Calibration was carried out using weighted linear estimates using Bayesian analysis. This was achieved using the POSTHOC function in NONMEM. In this method the population parameter estimates are used as the Bayesian prior. For the purposes of this estimation, the interindividual error on the input rate parameter (ka) was modelled as exponential (log normal). This was necessary in order to constrain this parameter due to the lack of data available for this phase.
Secondary pharmacokinetic parameters Individual parameter estimates from Bayesian analysis were imported into SAS/Win Version 6.08 [7] in order to compare the pharmacokinetic parameters for MP suleptanate relative to MP succinate. The mean (±s.e.mean) t 1/2,z for patients was estimated as 0.693/l z , where l z was obtained from the individual estimates of CL and V (l z =CL/V ). The area under the concentration time curve (AUC) at steady-state was estimated from individual parameter estimates of CL corrected for bioavailability ( F) using the following equation:
AUC SS = F.DOSE CL Steady-state t max (t maxss ) and C max (C maxss ) were calculated using the following equations:
.(e t maxss )−(e ka.t maxss )
where t is the dosing interval of 6 h.
Results
Plasma samples for pharmacokinetic analysis over a 48 h period were available from 90 patients participating in the study. A reasonable fit was obtained for the MP plasma concentration time data for both MP suleptanate and MP succinate using a first order input with mono-exponential elimination despite the high interindividual variability in covariates individually to the parameters ( These observations indicate that in asthmatic patients any minor differences in the population pharmacokinetic paramh). Although the estimated C max values were higher for MP suleptanate (698.4 ng ml −1 ) than MP succinate eters for MP suleptanate compared to MP succinate are unlikely to be significant in terms of safety and efficacy. (647.8 ng ml −1 ), this difference was not significantly different due to the higher variability observed for the MP
